Epstein-barr virus infections

EBV: A hidden player

More and more people are suffering from persistent and largely unexplained symptoms (Fig. 1). The real causes are often undetected.

Do you also have a wide range of similar symptoms? Have you or your doctor ever considered the potential impact of the Epstein-Barr virus (EBV)?

Clinical experience of practitioners of micro-immunotherapy has shown that these manifestations are indicative of a reactivation of this virus. Therefore, in order to avoid multiple potential misdiagnoses, it is convenient to rule out diagnostically an EBV burden in these cases.

Furthermore, this virus, which is the most common cause of glandular fever (also known as mononucleosis), has also been associated with a wide range of different diseases (Fig. 2).

Hence, it is important to detect EBV and treat it if a viral burden is confirmed, thereby positively influencing the course of the illness, and paving the way towards health. Since the immune system plays an important role in controlling the EBV infection, immunomodulatory treatments like micro-immunotherapy may be of great help.

The formula used to treat EBV infections is aimed at inhibiting virus replication and/or infection of other cells via a specific combination of immunomodulatory substances (including cytokines) and nucleic acids in low doses, thereby supporting the function of the immune system at the same time.

The symptoms of Epstein-Barr virus reactivation and Post-COVID / Long COVID syndrome are often overlapping. The results of a recent study showed that 73,3% of the surveyed post-COVID patients were undergoing an EBV reactivation, suggesting that various Long COVID symptoms may be associated with an EBV reactivation induced by COVID-19 inflammation. EBV may therefore be an important player in the onset and persistence of this clinical picture.

These findings open new perspectives for the diagnosis and treatment of persistent COVID-19 and point toward EBV detection and control strategies as a promising therapeutic approach in Long COVID patients. If an EBV reactivation is confirmed through serology, bringing the virus under control may be an essential step toward recovery.

Micro-immunotherapy, an immunoregulatory treatment that communicates with the immune system through immune messenger substances in low doses, can contribute to recovery by inhibiting Epstein-Barr virus replication and/or infection of further cells, promoting the antiviral immune response and preventing the onset of EBV-associated diseases.

If you would like to learn more on micro-immunotherapy as part of an integrated prevention and treatment plan in SARS-CoV-2 infections, register to our our professional area to check the Brochure on Micro-immunotherapy & Post-COVID syndrome or contact us directly at micro-immunotherapy@micro-immunotherapy.com